New Risk • Jun 05
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$298k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$88m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding). Significant insider selling over the past 3 months (US$298k sold). Revenue is less than US$5m (US$1.9m revenue). Board Change • May 21
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Chair of the Scientific Advisory Board Gloria Sheynkman was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Anuncio • Apr 30
Quantum-Si Incorporated Announces Successful Sequencing on Integrated Proteus Instruments Quantum-Si Incorporated announced that the company has successfully demonstrated sequencing on integrated Proteus instruments. This milestone was achieved using a developmental sequencing kit, the KinetIQ Array, and fully integrated Proteus instruments. The developmental sequencing kit used to achieve this milestone can detect 17 amino acids, a rapid improvement in only four months since adding the detection of the 15th amino acid to the commercially available sequencing kit in December of 2025. To demonstrate the full workflow, a sample, sequencing reagents and kinetic array were placed in the instrument drawer by the user and the run was initiated. The entire process from setting up the sequencing reaction to loading the sample into the KinetIQ Array through to data acquisition was fully automated by the Proteus instrument without any user intervention. Anuncio • Apr 16
Quantum-Si incorporated to Report Q1, 2026 Results on May 07, 2026 Quantum-Si incorporated announced that they will report Q1, 2026 results on May 07, 2026 Anuncio • Apr 09
Quantum-Si Incorporated Tests First Customer Samples on Proteus Prototype System Quantum-Si Incorporated announced that the Company has completed the sequencing of multiple samples provided by an existing Platinum Pro customer on a Proteus prototype system. The testing included sequencing the samples on both Platinum Pro and a Proteus prototype system. For Platinum Pro, the Company used the commercially available Version 3 Library Preparation Kit and Version 4 Sequencing Kit. For the Proteus prototype, the Company used the Version 3 Library Preparation Kit and a developmental sequencing kit that contains the latest amino acid recognizer set. The sequencing results were consistent with the information that the Company shared at the November 2025 Investor and Analyst Day demonstrating that Proteus was far exceeding Platinum Pro performance across all relevant metrics. Specifically, the Proteus prototype and developmental sequencing kit demonstrated significantly improved amino acid coverage, longer read lengths, more peptides identified and greater sequencing output even when normalized for the difference in the number of nanowells on a Platinum Pro chip versus the Proteus KinetIQ array. Anuncio • Apr 02
Quantum-Si incorporated, Annual General Meeting, May 15, 2026 Quantum-Si incorporated, Annual General Meeting, May 15, 2026. Anuncio • Mar 04
Quantum-Si incorporated Provides Earnings Guidance for the Full Year 2026 Quantum-Si incorporated provided earnings guidance for the full year 2026. For the period, the company expects revenue to be approximately $1.0 million. Anuncio • Feb 10
Quantum-Si incorporated to Report Q4, 2025 Results on Mar 03, 2026 Quantum-Si incorporated announced that they will report Q4, 2025 results on Mar 03, 2026 Anuncio • Feb 06
Quantum-Si Incorporated Announces the Release of Two New Manuscripts Demonstrating the Value of Single-Molecule Protein Sequencing in Clinical Proteomics and Pathogen & Toxin Detection Quantum-Si Incorporated announced two new manuscripts have been released, one as a peer reviewed publication in the Journal of Analytical Chemistry and one via preprint on ChemRxiv. The preprint has also been submitted for peer review. In the first paper, titled "Exploration of Semiconductor Chip-Based Single-Molecule Protein Sequencing for Identification of Hemoglobin Variants", the authors demonstrate the ability of Quantum-Si's protein sequencing technology to directly identify clinically relevant hemoglobin variants from blood samples that are difficult to detect by traditional methods. The authors concluded that as the sequencing coverage increases, Quantum-Si's protein sequencing Technology will be well positioned as a tool in clinical proteomics and hemoglobinopathy research. Anuncio • Nov 20
Quantum-Si Incorporated to Highlight Significant Proteus Platform Development Progress and Provide Insights into the Technology Pipeline At Investor & Analyst Day Quantum-Si Incorporated announced the key items to be presented at its Investor & Analyst Day that is being hosted in New York City. Among other advances, the management team will provide updates on: Proteus™? platform development including recent development data; A long-term technology roadmap that addresses the path to billions of reads; The path to coverage of all 20 amino acids; A suite of post-translational modification (PTM) methods enabled by the Company's core technology; The path to Proteus commercial launch including timeline and key technical and commercial milestones. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway, anticipated data and product launches (including Proteus), investor confidence in Quantum-Si and strategic roadmap, and any financial guidance. Factors that may cause such differences include, but are not limited to: the ability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth and retain its key employees; the Company's ongoing leadership transitions and succession planning; changes in applicable laws or regulations; the ability of the company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities, including the use and benefit of artificial intelligence in these and other activities; the commercialization and adoption of the Company's existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company's commercialized Platinum protein sequencing instruments and kits and the Company's other products (including Proteus) once commercialized; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; the Company's defense and initiation of litigation matters; and other risks and uncertainties described under "Risk Factors" in the company's defense and initiation of legal matters; and other risks and risks and uncertainties described under theRisk Factors" in the company's financial performance; and other risks and uncertainties. Anuncio • Oct 13
Quantum-Si incorporated to Report Q3, 2025 Results on Nov 05, 2025 Quantum-Si incorporated announced that they will report Q3, 2025 results on Nov 05, 2025 Anuncio • Jul 14
Quantum-Si incorporated to Report Q2, 2025 Results on Aug 05, 2025 Quantum-Si incorporated announced that they will report Q2, 2025 results on Aug 05, 2025 Anuncio • Jul 04
Quantum-Si incorporated has filed a Follow-on Equity Offering in the amount of $49.999999 million. Quantum-Si incorporated has filed a Follow-on Equity Offering in the amount of $49.999999 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 29,940,119
Price\Range: $1.67
Transaction Features: Registered Direct Offering Anuncio • Jun 11
Quantum-Si Incorporated's Single-Molecule Tech Enables Precise, Multiplexed Measurement of Nanobody Binding in A Single Assay Quantum-Si Incorporated announced a new preprint from researchers at Quantum-Si and ESPCI Paris that introduces a powerful method for measuring single-molecule binding kinetics at scale. The approach directly links nanobody function to identity without the need for genotype-phenotype coupling. The team validated their results across 20 nanobody variants with more than a 1,000-fold range in affinity, showing strong correlation with surface plasmon resonance (SPR), a gold standard in binding analysis. The extended dynamic range allows for the single-molecule characterization of high-affinity antibodies, an area that has seen limited exploration and that could open up new possibilities in multiple applications. While this proof-of-concept study focused on 20 variants, with upcoming chemistry and hardware updates, the system has the potential to scale to over 1,000-member barcode sets. Future technological developments to expand the size of reaction chamber may allow similar increases in the size of variant panels. This makes it ideally suited for applications in synthetic biology, drug discovery, and AI-driven protein engineering. Quantum-Si is seeking partners to advance Quantum-Si's platform, across innovative applications including nanobody research, ultrasensitive protein detection, and beyond. If interested, apply via Technology Access Program. The preprint entitled "Parallelization of single-molecule binding kinetic measurements via protein barcode sequencing," is now available at: Quantum-Si Resources. Anuncio • Apr 24
Quantum-Si incorporated to Report Q1, 2025 Results on May 15, 2025 Quantum-Si incorporated announced that they will report Q1, 2025 results on May 15, 2025 Anuncio • Mar 27
Quantum-Si Incorporated Begins Shipping Platinum® Pro, Advancing Accessibility in Next-Gen Protein Sequencing™ Quantum-Si Incorporated announced the start of shipments for its latest benchtop sequencer, Platinum® Pro. This instrument offers protein analysis with single-molecule precision, aiming to make Next-Gen Protein Sequencing™ more accessible to laboratories worldwide. Platinum Pro delivers a comprehensive solution for sequencing and analyzing proteins through a simple, integrated workflow. Building upon the foundation of innovation established by the original Platinum, the new system introduces advanced features tailored to the evolving needs of researchers and biopharmaceutical customers. Key innovations include: Streamlined User Experience: An enlarged touchscreen with an intuitive user interface guides users through each run, supporting diverse applications from proteoform analysis to protein barcoding. Flexible Data Analysis: Options for local or cloud-based data analysis provide versatility to suit various research environments. Pro Mode: This feature empowers custom application development, offered through a Technology Access Program, positioning Platinum Pro as a platform for biopharmaceutical innovation and application co-development. Platinum Pro exemplifies Quantum-Si’s dedication to progressive innovation that delivers solutions for Next-Gen Protein Sequencing. With its robust capabilities, the system is expected to drive new opportunities for breakthrough discoveries. Platinum Pro shipments have started, and the system is available in more than 30 countries through Quantum-Si’s direct and channel partner network, marking a significant milestone in making advanced proteomics tools more accessible to every lab, everywhere. Anuncio • Mar 21
Quantum-Si incorporated, Annual General Meeting, May 16, 2025 Quantum-Si incorporated, Annual General Meeting, May 16, 2025. Anuncio • Mar 04
Quantum-Si incorporated Provides Revenue Guidance for the First Quarter of 2025 Quantum-Si incorporated provided revenue guidance for the first quarter of 2025. For the first quarter of 2025, the company anticipated revenue to be at least $900,000. Anuncio • Feb 19
Quantum-Si incorporated to Showcase Next-Generation Protein Sequencing at AGBT 2025 Quantum-Si Incorporated and several distinguished researchers will be presenting new research and applications at the 2025 Advances in Genome Biology and Technology (AGBT) General Meeting February 23-26, 2025. Quantum-Si, the pioneer in Next-Generation Protein Sequencing (NGPS™) will feature research through one company-led poster and two customer-led posters highlighting the transformative capabilities of NGPS in multi-omics research and drug discovery. Scientific Posters Highlighting NGPS Innovation: Beyond the genome: Advancing understanding of the proteome with Next-Generation Protein Sequencing: Introduces how NGPS offers an integrated understanding of cellular processes by detecting changes at the protein level (such as post-translational modifications, or PTMs) that cannot be captured by genomics data alone. Integrating long-read RNAseq and Next-Generation Protein Sequencing™ to explore proteoform variability: Demonstrates the integration of long-read RNA sequencing to capture transcript isoforms, combined with the benchtop instrument Platinum™ to produce single-molecule peptide sequencing data. Identifying Protein Binding Partners at the Bench Using Quantum-Si: Demonstrates how NGPS enables direct peptide sequencing to identify protein partners regulated by genomic, epigenomic, or splicing variation, offering a rapid and cost-effective alternative to legacy technologies. Anuncio • Feb 12
Quantum-Si incorporated to Report Q4, 2024 Results on Mar 03, 2025 Quantum-Si incorporated announced that they will report Q4, 2024 results at 12:30 PM, US Eastern Standard Time on Mar 03, 2025 Anuncio • Feb 06
Quantum-Si Incorporated Announces Formation of Scientific Advisory Board Quantum-Si Incorporated announced the formation of its Scientific Advisory Board. Comprised of distinguished experts in proteomics, genomics, bioinformatics, chemistry, and engineering, the board will play a critical role in shaping Quantum-Si’s scientific and development strategy, identifying emerging trends and applications, and strengthening engagement within the scientific community. Dr. Gloria M. Sheynkman, a leading expert in proteoform characterization and single-molecule protein sequencing, has been named Chair of the Scientific Advisory Board. Dr. Sheynkman is an Assistant Professor at the University of Virginia with joint appointments in Molecular Physiology and Biological Physics, and Biochemistry and Molecular Genetics. Her research integrates advanced mass spectrometry, long-read RNA sequencing, and single-molecule protein sequencing to map and characterize diverse proteoforms, providing new insights into complex diseases such as cardiovascular disease and cancer. A recipient of numerous awards, she is actively involved in key professional organizations, including the American Society for Mass Spectrometry (ASMS) and the Human Proteome Organization (HUPO). Joining Dr. Sheynkman on the SAB are: Dr. Benjamin A. Garcia – A globally recognized leader in mass spectrometry-based proteomics, Dr. Garcia is the Raymond H. Wittcoff Distinguished Professor and Head of the Department of Biochemistry and Molecular Biophysics at Washington University School of Medicine in St. Louis. His research focuses on developing novel proteomic and bioinformatics approaches to study protein modifications and their role in epigenetic regulation and disease. He has published over 450 scientific papers and holds leadership positions in HUPO, US HUPO, ASMS, and the ACS. Dr. Bradley L. Pentelute – A Professor of Chemistry at Massachusetts Institute of Technology (MIT) and an Associate Member of the Broad Institute of Harvard and MIT, Dr. Pentelute’s research explores peptide and protein synthesis, bioengineering, and molecular delivery systems. His expertise in chemical biology and peptide therapeutics brings a valuable perspective to Quantum-Si’s efforts to expand protein sequencing applications. Dr. Denis Zaccarin – A seasoned expert in semiconductor technology and consumable development for sequencing platforms, Dr. Zaccarin previously held senior leadership positions at Pacific Biosciences of California (PacBio), including Senior Vice President of Research and Development. With extensive experience in engineering and optical systems, he will provide strategic insights into the development of Quantum-Si’s next-generation technology. The Scientific Advisory Board will support Quantum-Si in prioritizing key applications, fostering collaborations, and driving awareness of NGPS within the broader scientific community. Anuncio • Jan 13
Quantum-Si incorporated Launches Platinum® Pro: the End-To-End Solution for Deeper Insights in Proteomics Quantum-Si incorporated announces the launch of Platinum Pro, its latest benchtop sequencer that sets a new standard in protein analysis. Designed to redefine efficiency and versatility in proteomics research, Platinum Pro is now available for ordering. Platinum Pro delivers a comprehensive solution for sequencing and analyzing proteins in a simple, integrated workflow. Its design prioritizes accessibility, transforming complex protein sequencing into a seamless process for every lab, everywhere. Platinum Pro is Quantum-Si’s newest Next-Generation Protein Sequencer™ built from the foundation of innovation established by the original Platinum. It introduces advanced features specifically tailored to address the evolving needs of researchers and biopharmaceutical customers. Its key innovations include: Streamlined User Experience: Platinum Pro features an enlarged touchscreen with an elegant user interface that guides the user through the course of a run enabling diverse applications from proteoform analysis to protein barcoding and beyond. Flexible Data Analysis: Users can perform data analysis locally or leverage cloud-based solutions, providing versatility to suit diverse research environments.
Pro Mode: This feature empowers custom application development, offered through a Technology Access Program, making Platinum Pro a platform for biopharmaceutical innovation and co-development relationships. Platinum Pro is the latest demonstration of Quantum-Si’s commitment to delivering cutting-edge solutions for next-generation protein sequencing. Anuncio • Nov 20
Quantum-Si to Develop Acceleration Platform and Advance Core Technologies in Collaboration with Nvidia Quantum-Si Incorporated announced a collaboration with NVIDIA to develop its new proteomics platform, Proteus™, and advance Quantum-Si’s core technologies of amino acid binders and aminopeptidases using NVIDIA AI and accelerated computing. This collaboration aims to significantly enhance data processing speeds to handle the increased data volume from Proteus. By leveraging NVIDIA accelerated computing and Quantum-Si’s advanced single-molecule protein sequencing and detection technologies, the collaboration aims to develop a robust data processing system. This system will keep pace with Quantum-Si’s rapidly evolving technology advancements, generating single-molecule protein insights to deepen understanding of the proteome and develop innovative solutions through research, drug discovery, and healthcare AI. Anuncio • Nov 10
Quantum-Si incorporated Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement On November 4, 2024, Quantum-Si Incorporated (the Company") received written notice (the Notice") from the Listing Qualifications Department (the Staff") of The Nasdaq Stock Market LLC (Nasdaq") notifying the Company that, because the closing bid price for the Company's Class A common stock, par value $0.0001 per share (the Common Stock"), has fallen below $1.00 per share for 30 consecutive business days, the Company no longer meets the minimum bid price requirement for continued inclusion on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the Bid Price Requirement"). This Notice has no immediate effect on the listing or trading of the Company's Common Stock, which continues to trade on The Nasdaq Global Market under the symbol QSI". The Notice also does not affect the ongoing business operations of the Company or its reporting requirements with the Securities and Exchange Commission. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A) (the Compliance Period Rule"), the Company has been provided an initial period of 180 calendar days, or until May 5, 2024, (the Compliance Date") to regain compliance with the Bid Price Requirement. To regain compliance, the closing bid price of the Company's Common Stock must be at least $1.00 per share for a minimum of 10 consecutive business days as required under the Compliance Period Rule (unless the Staff exercises its discretion to extend this ten-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H)). If the Company does not regain compliance with the Bid Price Requirement by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company would need to transfer the listing of its Common Stock to The Nasdaq Capital Market and meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards, with the exception of the Bid Price Requirement. To effect such a transfer, the Company would also need to pay an application fee to Nasdaq and would need to provide written notice to the Staff of the Company's intention to cure the deficiency during the additional compliance period. If the Staff concludes that the Company will not be able to cure the deficiency, or if the Company does not regain compliance with the Bid Price Requirement within such additional 180 calendar day compliance period, the Staff will provide written notification to the Company that the Company's Common Stock will be subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a Nasdaq Hearings Panel (the Panel"). However, there can be no assurance that, if the Company receives a delisting notice and appeals
the delisting determination by the Staff to the Panel, such appeal would be successful. The Company intends to monitor the closing bid price of its Common Stock and will consider all available options to regain compliance with the Bid Price Requirement. However, there can be no assurance that the Company will be able to regain compliance with the Bid Price Requirement or that the Staff will grant the Company a further extension of time to regain compliance, if applicable. Anuncio • Nov 08
University of Virginia Researchers Publish New Study on Tropomyosin Proteoforms Showcasing Quantum-Si's Next-Gen Protein Sequencer™? Platinum Quantum-Si Incorporated announced a newly released preprint publication on BioRxiv, from Dr. Gloria Sheynkman at the University of Virginia School of Medicine. In the publication, Sheynkman and team demonstrate the application of Quantum-Si's Platinum™? single-molecule benchtop sequencer to distinguish proteoform-informative peptides within the human tropomyosin (TPM) gene family. This study highlights Platinum's ability to achieve single amino acid resolution, revealing variations that differentiate crucial tissue-specific and modified protein forms. The study further explores Platinum's capability to differentiate highly similar peptides that may define oforms with distinct functions. Platinum's single amino acid resolution enables it to detect sequences with molecular weights that challenge traditional mass spectrometry (MS) techniques, making it a complementary tool for MS and an asset for proteomics researchers focused on nuanced peptide differences. Anuncio • Oct 23
Quantum-Si incorporated to Report Q3, 2024 Results on Nov 12, 2024 Quantum-Si incorporated announced that they will report Q3, 2024 results on Nov 12, 2024 Anuncio • Aug 28
Quantum-Si Incorporated Announces Executive Changes Quantum-Si Incorporated announced that Todd Bennett will join QSI as the Company’s new Chief Commercial Officer effective September 16, 2024, John Vieceli, Ph.D. has been named Chief Product Officer and Lindsay Thompson has been named Chief Human Resources Officer. Mr. Bennett brings over 30 years of commercial leadership experience in life science tools and diagnostics to Quantum-Si. He brings expertise in building and leading teams across sales, marketing, customer service, business development, and strategy. Mr. Bennett has worked at industry leaders such as Luminex, Abbott, Roche and Immucor. Mr. Bennett holds a B.S. degree in Business Administration with an emphasis in finance from the Max M. Fisher College of Business at Ohio State University. Dr. Vieceli joined Quantum-Si in December of 2022 and prior to that has held leadership roles at top DNA sequencing companies, including Illumina, Omniome, and Pacific Biosciences, focusing on bioinformatics, signal processing, and computer subsystems. At Illumina, he received the 2022 Annual Innovation Award for advancements in signal processing that boosted sequencing accuracy. He is an inventor on over 25 issued patents and pending applications and has authored more than 20 scientific publications. Dr. Vieceli earned his Ph.D. in Theoretical Physical Chemistry from UC Santa Cruz and his B.S. in Biology and Chemistry from Santa Clara University. Ms. Thompson joined Quantum-Si in 2021 bringing a wealth of experience in human resources leadership across multiple industries spanning life sciences, financial services, distribution and manufacturing. Ms. Thompson received her B.S. in Business Administration and currently holds her SHRM (Society for Human Resources Management) certification. Finally, Grace Johnston, PhD., has resigned from her role as Chief Commercial Officer. Dr. Johnston will provide transitional support to the Company through September 6, 2024. The Company would like to thank Dr. Johnston for her contributions to Quantum-Si during her tenure. Anuncio • Jul 18
Quantum-Si incorporated to Report Q2, 2024 Results on Aug 07, 2024 Quantum-Si incorporated announced that they will report Q2, 2024 results on Aug 07, 2024 Anuncio • May 31
Quantum-Si Incorporated Announces Board Changes Quantum-Si Incorporated announced the appointment of Charles (“Chuck”) Kummeth to the role of independent Chairman of the Board, effective May 27, 2024. Mr. Kummeth has over 35 years of leadership experience in Life Sciences most recently as President and CEO of Bio-Techne. During Mr. Kummeth’s tenure at Bio-Techne, he oversaw tremendous growth across all aspects of the business including annual revenue growth from $300 million to over $1.1 billion, growth in the employee base from 800 to over 3,000, and the successful execution of 19 acquisitions, all while maintaining a 35% or better EBITDA level. Under Mr. Kummeth’s leadership, Bio-Techne’s market capitalization grew from $2.2 billion to a high of $21 billion, culminating in an invitation for the company to join the S&P 500. Prior to Bio-Techne, Mr. Kummeth served as President of Mass Spectrometry and Chromatography and President of the Laboratory Consumables Division at Thermo Fisher Scientific Inc. Prior to joining Thermo Fisher, Mr. Kummeth served in various roles during his 24-year career at 3M Corporation, culminating as the Vice President of the company's Medical Division. Dr. Jonathan Rothberg, who has served as Chairman of the Board since inception, will remain a member of the Board of Directors of the Company going forward. Mr. Kummeth received a BS in Electrical Engineering from the University of North Dakota, and a MS in Computer Science from the University of St. Thomas and an MBS from the Carlson School of Business at the University of Minnesota. Mr. Kummeth also serves on the boards of Gentherm, a thermal management technology company, PerkinElmer, a life sciences company, and Orthofix, a global spine and orthopedics company. Anuncio • May 10
Quantum-Si Incorporated Reaffirms Earnings Guidance for the Full Year 2024 Quantum-Si incorporated reaffirmed earnings guidance for the full year 2024. For the year, the company expected revenue to be in the range of $3.7 million to $4.2 million. Anuncio • Apr 30
Quantum-Si Incorporated Announces Upgrades to Analysis Software that will Provide Customers with Higher Data Output and Precision and Shorter Processing Time Quantum-Si Incorporated announced upgrades to its Platinum® Analysis Software to reduce processing time and increase output and precision of Next-Generation Protein Sequencing™ (NGPS) data from the Platinum® instrument. Innovations in this release of the Platinum Analysis Software will provide customers with an average of: 55% increase in the number of peptide alignments of protein samples, 9% increase in the precision of identifying unknown proteins present in a given sample and 70% reduction in primary analysis time from 85 minutes to 25 minutes. Anuncio • Apr 20
Quantum-Si incorporated to Report Q1, 2024 Results on May 09, 2024 Quantum-Si incorporated announced that they will report Q1, 2024 results on May 09, 2024 Anuncio • Apr 02
Quantum-Si incorporated, Annual General Meeting, May 15, 2024 Quantum-Si incorporated, Annual General Meeting, May 15, 2024, at 12:00 US Eastern Standard Time. Agenda: To elect nine directors to serve one-year terms expiring in 2025; to ratify the appointment of Deloitte & Touche LLP as company independent registered public accounting firm for the fiscal year ending December31, 2024; to approve, by a non-binding, advisory vote, the compensation of company named executive officers, as disclosed in this proxy statement; to approve proposed amendments (the Director Cap Amendments) to company second amended and restated certificate of incorporation; to approve a proposed amendment (the Sunset Amendment) to our Certificate of Incorporation to add a provision with respect to the automatic conversion of company ClassB common stock effective June10, 2028, which is seven years from the date of the closing of company business combination by and among Quantum-Si; and to transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof. Anuncio • Mar 22
Quantum-Si Incorporated Appoints Paula Dowdy to the Board of Directors Quantum-Si Incorporated announced the appointment of Paula Dowdy, a senior executive with more than 35 years of experience across life sciences, enterprise software, and technology industries, to its Board of Directors. Ms. Dowdy currently serves on the Board of Directors for SPT Labtech and is an advisor at EQT Life Sciences. Previously, she was the SVP and General Manager of Europe, Middle East and Africa (EMEA) at Illumina where she led the region through a period of significant growth. Prior to Illumina, Ms. Dowdy spent over 20 years at Cisco Systems Inc. and held various positions in products, services, and software in the United States, and globally. Throughout her career, Ms. Dowdy has demonstrated a commitment to supporting companies as they scale and helping them achieve record revenue growth. Her expertise in commercial strategy, market development, and global operations will be instrumental as Quantum-Si continues to expand its reach and impact in proteomics. Ms. Dowdy earned an MBA from Pepperdine University and a Bachelor of Arts degree from the University of California, Berkeley. Her appointment to the company’s Board of Directors is effective as of March 21, 2024. Recent Insider Transactions • Mar 09
CFO & Treasurer recently bought US$81k worth of stock On the 5th of March, Jeffry Keyes bought around 50k shares on-market at roughly US$1.61 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Jeffry's only on-market trade for the last 12 months. Anuncio • Mar 02
Quantum-Si Incorporated Provides Earnings Guidance for the Full Year 2024 Quantum-Si incorporated provided earnings guidance For the full year 2024. For the year, the Company expects Revenue to be $3.7 million - $4.2 million. Anuncio • Feb 10
Quantum-Si incorporated to Report Q4, 2023 Results on Feb 29, 2024 Quantum-Si incorporated announced that they will report Q4, 2023 results on Feb 29, 2024 Anuncio • Feb 05
Quantum-Si incorporated Expands Proteome Coverage and Increases Sequencing Output with New Enhancements to Its Next-Generation Protein Sequencing™ Platform Quantum-Si Incorporated announced the launch of new platform enhancements for Platinum®, with the release of its new V2 Sequencing Kits. Combined with its first-to-market, next-generation protein sequencer™, these enhancements enable: Increased sequencing performance with assay improvements, including the addition of a new amino acid recognizer; Ability to identify unknown proteins with advanced analytical and inference tools; High reproducibility across runs; and Approximately a 3-fold reduction in cost per amino acid. The company is now accepting orders for first-time and existing customers for the Protein Sequencing Kit V2. Anuncio • Jan 19
Quantum-Si Introduces Next-Generation Protein Sequencertm in Japan with Addition of New Distributor Quantum-Si Incorporated announced that it has entered into an agreement with a new distributor who will make the company's protein sequencing instrument, Platinum®? available for the first time in Japan. TOMY Digital Biology Co. Ltd. will distribute Quantum-Si's next-generation protein sequencertm and associated consumables throughout Japan. TOMY Digital Biology's commitment to delivering cutting-edge solutions and its alignment with Quantum-Si's vision for scientific innovation make this a significant step forward in providing researchers in Japan access to technology for next-generation protein sequencing™?. Price Target Changed • Nov 29
Price target decreased by 25% to US$1.50 Down from US$2.00, the current price target is provided by 1 analyst. New target price is 7.4% below last closing price of US$1.62. Stock is down 32% over the past year. The company is forecast to post a net loss per share of US$0.72 next year compared to a net loss per share of US$0.95 last year. Board Change • Nov 29
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 2 experienced directors. No highly experienced directors. Founder & Executive Chairman Jonathan Rothberg is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Anuncio • Oct 18
Quantum-Si incorporated to Report Q3, 2023 Results on Nov 09, 2023 Quantum-Si incorporated announced that they will report Q3, 2023 results on Nov 09, 2023 Anuncio • Sep 22
Quantum-Si Incorporated Announces Appointment of Amir Jafri to Its Board of Directors Quantum-Si Incorporated announced the appointment of Amir Jafri, President and CEO of Immunicom Inc., to its Board of Directors. Mr. Jafri has more than 35 years of experience in biotech, healthcare technology and devices, working in Fortune 20 companies and his own startups. In 2013, he founded Immunicom, a medical technology company focused on developing innovative, non-pharmaceutical approaches for the treatment of cancer, and inflammatory and autoimmune diseases. Previously, Mr. Jafri held executive leadership positions at West Health, Cardinal Health and the Manpower Group. Early in his career, he founded two healthcare startups that were subsequently acquired. Currently, he serves on the board of various healthcare technology startup companies and nonprofit organizations. Mr. Jafri is an inventor on over 40 patents covering products and technologies across a range of industries and applications. Mr. Jafri earned a Bachelor of Science from Houston Christian University with a double major in Chemistry and Biology and a minor in History. Anuncio • Sep 01
Quantum-Si incorporated Terminates Approximately 16% of its Workforce On August 26, 2023, Quantum-Si Incorporated committed to an organizational restructuring designed to decrease its costs and create a more streamlined organization to support its business. As a result, the Company is terminating approximately 16% of its workforce. Anuncio • Aug 31
Quantum-Si incorporated Announces Executive Changes On August 28, 2023 (Effective Date), Quantum-Si incorporated and Patrick Schneider, Ph.D., the Company’s current President and Chief Operating Officer, mutually determined that Dr. Schneider will step down from such roles, effective as of the Effective Date. In addition, the Company’s board of directors appointed Jeffrey Hawkins, the Company’s current Chief Executive Officer and member of the Board, as President of the Company, effective as of the Effective Date. Mr. Hawkins will also continue to serve as Chief Executive Officer and member of the Board. Major Estimate Revision • Aug 14
Consensus revenue estimates decrease by 58%, EPS upgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$3.30m to US$1.40m. EPS estimate increased from -US$0.77 to -US$0.75 per share. Life Sciences industry in the US expected to see average net income growth of 9.4% next year. Consensus price target down from US$4.00 to US$3.50. Share price fell 3.9% to US$2.21 over the past week. Anuncio • Jul 21
Quantum-Si incorporated to Report Q2, 2023 Results on Aug 07, 2023 Quantum-Si incorporated announced that they will report Q2, 2023 results on Aug 07, 2023 New Risk • Jul 18
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m (US$254k revenue). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$105m net loss in 3 years). Anuncio • Jun 22
Quantum-Si Incorporated Announces Executive Changes Quantum-Si Incorporated announced the appointment of Johan Denecke as Senior Vice President of Operations, effective June 20, 2023. Mr. Denecke will be responsible for scaling up production and driving operational and quality excellence in support of the commercialization of Quantum-Si’s next-generation, single-molecule protein sequencing platform. Mr. Denecke brings more than 20 years of experience as a cross-functional operations executive in engineering, quality assurance and best-in-class manufacturing practices. Having held executive positions in both private and public sectors, including at Illumina as Vice President of Manufacturing Engineering, and Thermo Fisher Scientific as Vice President of Quality Assurance, he brings a wealth of experience to the table. Most recently, he served as Senior Vice President of Operations at Atomica where he scaled the organization yielding significant growth, efficiency, and waste reduction. Mr. Denecke holds a Bachelor of Science and Master of Science in aerospace engineering from the Massachusetts Institute of Technology. Michael McKenna, Ph.D., whose service and leadership were integral to the Company’s product development and pre-revenue stage, will transition out of his role as Executive Vice President of Product Development and Operations at Quantum-Si at the end of July 2023. Anuncio • May 23
Quantum-Si Incorporated Appoints John Patrick Kenny to the Board Quantum-Si incorporated appointed John Patrick Kenny to the Board, effective as of May 19, 2023. The Board also appointed Mr. Kenny to serve on the Nominating and Corporate Governance Committee and Compensation Committee of the Board. Mr. Kenny will serve for a term to continue until the Company’s next annual meeting of stockholders. Mr. Kenny, age 54, has over 30 years of operational and commercial leadership experience. Mr. Kenny has served as Meridian Bioscience Inc.’s (“Meridian”) Chief Executive Officer and on its board of directors since October 2017. Prior to his role at Meridian, Mr. Kenny served as Senior Vice President and General Manager, North America, of Siemens Healthcare from October 2014 to May 2017. From 2012 to 2014, Mr. Kenny served as Vice President and General Manager, U.S. Region, for Becton Dickinson, Diagnostic Systems. Prior to 2012, he held executive roles at Danaher Corporation and Quest Diagnostics. Mr. Kenny received his B.S. degree in Management Systems from Kettering University. Mr. Kenny’s qualifications to serve on the Board include his operational experience as the Chief Executive Officer of a publicly traded company, along with his executive leadership in the healthcare and medical device industries. Major Estimate Revision • May 18
Consensus revenue estimates decrease by 60%, EPS upgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$8.30m to US$3.30m. EPS estimate increased from -US$0.79 to -US$0.77 per share. Life Sciences industry in the US expected to see average net income growth of 6.2% next year. Consensus price target of US$4.00 unchanged from last update. Share price fell 12% to US$1.44 over the past week. Anuncio • Feb 14
Quantum-Si incorporated to Report Q4, 2022 Results on Mar 06, 2023 Quantum-Si incorporated announced that they will report Q4, 2022 results Pre-Market on Mar 06, 2023 Recent Insider Transactions • Dec 18
Director recently sold US$191k worth of stock On the 15th of December, Kevin Rakin sold around 89k shares on-market at roughly US$2.15 per share. This transaction amounted to 93% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$1.2m more than they bought in the last 12 months. Board Change • Nov 16
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 1 experienced director. No highly experienced directors. Founder & Executive Chairman Jonathan Rothberg is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Major Estimate Revision • Nov 03
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$0.85 to -US$1.03 per share. Revenue forecast of US$700.0k unchanged since last update. Life Sciences industry in the US expected to see average net income growth of 5.2% next year. Consensus price target down from US$7.00 to US$5.00. Share price fell 6.2% to US$2.87 over the past week. Anuncio • Oct 18
Quantum-Si incorporated to Report Q3, 2022 Results on Nov 07, 2022 Quantum-Si incorporated announced that they will report Q3, 2022 results After-Market on Nov 07, 2022 Anuncio • Oct 05
Quantum-Si Incorporated Appoints Jeff Hawkins as Chief Executive Officer Quantum-Si incorporated announced the appointment of Jeff Hawkins as Chief Executive Officer. Mr. Hawkins will succeed Dr. Jonathan Rothberg, Founder and Executive Chairman of Quantum-Si, who has also been serving as Interim Chief Executive Officer, and lead the next phase of growth as the Company prepares to launch the Platinum™ instrument, which will be the industry’s first system to enable next generation, single-molecule protein sequencing. This appointment is effective October 10, 2022. Mr. Hawkins brings over 20 years of experience at the world’s leading life science and diagnostics companies as an accomplished business leader and inventor. Prior to Quantum-Si, he was President and Chief Executive Officer of Truvian Sciences Inc. where he led the evolution of the company’s benchtop blood testing system from a product concept through technology feasibility and into late-stage development. Prior to Truvian, Mr. Hawkins led the Reproductive and Genetic Health Business Unit at Illumina Inc., where he oversaw the rapid global growth of next-generation sequencing into new and emerging markets. During his Illumina tenure, the business unit more than doubled in revenue and established clear market leadership across every major product line and geographic region. Before Illumina, Mr. Hawkins held roles of increasing responsibility across multiple functional areas for GenMark, Hologic, Third Wave Technologies and Abbott Laboratories. Mr. Hawkins holds a B.A. in Chemistry with honors from Concordia University and an MBA from Keller Graduate School of Management. He is co-inventor on 10 issued or pending patents spanning consumables, instrumentation, optics, manufacturing methods and designs. Recent Insider Transactions • Aug 20
General Counsel & Corporate Secretary recently bought US$79k worth of stock On the 17th of August, Christian Lapointe bought around 20k shares on-market at roughly US$3.93 per share. In the last 3 months, there was an even bigger purchase from another insider worth US$79k. Despite this recent purchase, insiders have collectively sold US$1.0m more in shares than they bought in the last 12 months. Major Estimate Revision • Aug 16
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$2.10m to US$700.0k. EPS estimate increased from -US$1.01 to -US$0.85 per share. Life Sciences industry in the US expected to see average net income growth of 5.4% next year. Consensus price target of US$7.00 unchanged from last update. Share price rose 14% to US$4.08 over the past week. Major Estimate Revision • Aug 02
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$4.70m to US$2.10m. EPS estimate increased from -US$1.25 to -US$1.01 per share. Life Sciences industry in the US expected to see average net income growth of 6.6% next year. Consensus price target down from US$10.00 to US$7.00. Share price rose 9.7% to US$3.27 over the past week. Anuncio • Jul 19
Quantum-Si incorporated to Report Q2, 2022 Results on Aug 08, 2022 Quantum-Si incorporated announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 08, 2022 Recent Insider Transactions • Jun 18
Founder recently bought US$79k worth of stock On the 14th of June, Jonathan Rothberg bought around 26k shares on-market at roughly US$3.10 per share. This was the largest purchase by an insider in the last 3 months. This was Jonathan's only on-market trade for the last 12 months. Anuncio • Jun 17
Quantum-Si Appoints Vikram Bajaj, Ph.D., to Board of Directors Quantum-Si Incorporated announced the appointment of Vikram Bajaj, Ph.D., co-founder and former Chief Scientific Officer of Verily (formerly Google Life Sciences), to its Board of Directors. Dr. Bajaj is a managing director at Foresite Capital, evaluating and pursuing investments at the intersection of technology and life sciences, including in personalized and precision healthcare. Prior to joining Foresite Capital, Vik was the Chief Scientific Officer of GRAIL and remains on its Scientific Advisory Board. He is also the co-founder and former Chief Scientific Officer of Verily (formerly Google Life Sciences) and served as chair of its Scientific Advisory Board. Bajaj retains appointments as associate professor at the Stanford University School of Medicine, and as an affiliate scientist of the Lawrence Berkeley National Laboratory and the University of California, Berkeley, for which he serves on the advisory board of the College of Chemistry. He is an advisor to the Department of Defense through the Defense Science Board’s Task Force on Biology. Bajaj holds a Ph.D. in physical chemistry from the Massachusetts Institute of Technology. His scientific and engineering awards include the Anatole Abragam Prize (2012), the R&D 100 Award for the most promising commercialized technologies (2011 and 2013), and the Department of Energy’s LBL Innovation Grant (2013). In 2011, he was named as a Visiting Professor of the Chinese Academy of Sciences. Anuncio • Jun 11
Quantum-Si Incorporated Announces Resignation of Matthew Dyer as Chief Business Officer, Effective from June 15, 2022 On June 9, 2022, Matthew Dyer, Ph.D. delivered his resignation as Quantum-Si Incorporated’s (the “Company”) Chief Business Officer, effective as of June 15, 2022 (the “Effective Date”). In connection with Dr. Dyer’s termination of employment, the Company and Dr. Dyer entered into a separation agreement (the “Separation Agreement”), dated as of June 10, 2022, which provides, among other things, that (i) the Company will pay Dr. Dyer severance pay equal to $300,000, or nine months of his current annual base salary, payable on the Company’s first regularly scheduled payroll date following the Effective Date; and (ii) for the period of July 1, 2022 through March 31, 2023, the Company will pay the costs of Dr. Dyer’s COBRA health insurance if he enrolls in COBRA coverage; provided that Dr. Dyer does not revoke the Separation Agreement on or before June 17, 2022. The Separation Agreement also includes other customary provisions. Major Estimate Revision • May 17
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$0.97 to -US$1.25 per share. Revenue forecast of US$4.70m unchanged since last update. Life Sciences industry in the US expected to see average net income growth of 7.3% next year. Consensus price target down from US$12.00 to US$10.00. Share price rose 11% to US$3.74 over the past week. Anuncio • May 10
Quantum-Si Incorporated Appoints Patrick Schneider as President and Chief Operating Officer Quantum-Si incorporated announced the appointment of Patrick Schneider, Ph.D., as President and Chief Operating Officer (COO). Schneider will succeed Michael McKenna, Ph.D., who will remain as Executive Vice President, Product Development and Operations. Schneider brings over 25 years of experience as an accomplished life science leader and entrepreneur. Schneider joins Quantum-Si from MilliporeSigma, where he most recently served as Senior Vice President of Strategy, Business Development and Innovation, and Chair of the Life Science Innovation Board. During his 16-year tenure with MilliporeSigma and its predecessor entities, Schneider held roles of increasing responsibility and led strategy development for the Research Solutions Business Unit, executed over 250 technology access, co-development and distribution agreements, developed in- and out-licensing strategies, and oversaw a global team of over 300 biologists, chemists and engineers. Price Target Changed • Apr 27
Price target decreased to US$12.00 Down from US$13.00, the current price target is provided by 1 analyst. New target price is 178% above last closing price of US$4.31. Stock is down 58% over the past year. The company is forecast to post a net loss per share of US$0.97 next year compared to a net loss per share of US$1.19 last year. Board Change • Apr 27
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Founder, CEO & Executive Chairman Jonathan Rothberg is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Anuncio • Apr 19
Quantum-Si incorporated to Report Q1, 2022 Results on May 09, 2022 Quantum-Si incorporated announced that they will report Q1, 2022 results After-Market on May 09, 2022 Anuncio • Mar 31
Quantum-Si incorporated, Annual General Meeting, May 10, 2022 Quantum-Si incorporated, Annual General Meeting, May 10, 2022, at 15:30 US Eastern Standard Time. Agenda: To elect six directors to serve one-year terms expiring in 2023; to ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022; to approve by an advisory vote the frequency of holding an advisory vote on compensation of our named executive officers; and to transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof. Anuncio • Mar 30
James Tananbaum, M.D. Will Retire from Board of Directors James Tananbaum, M.D. will retire from board of directors of Quantum-Si incorporated at the conclusion of the 2022 annual meeting of stockholders, to be held on May 10, 2022. Anuncio • Feb 15
Quantum-Si Incorporated Announces Executive Changes Quantum-Si Incorporated announced the appointment of Dr. Jonathan Rothberg, Founder and Executive Chairman of Quantum Si’s Board of Directors, as Interim CEO. Dr. Rothberg succeeds John Stark, effective February 8, 2022, while the Company’s Board of Directors commences a search process to identify a long-term CEO. Dr. Rothberg is a prolific inventor, scientist and entrepreneur who has successfully founded and launched multiple life science and medical device companies, including 454 Life Sciences, AI Therapeutics, Butterfly Network, CuraGen, Detect, Hyperfine, Ion Torrent, Liminal Sciences, Protein Evolution, RainDance Technologies, Tesseract Health and Quantum-Si. In 2006, Dr. Rothberg was awarded the National Medal of Technology and Innovation by President Barack Obama for pioneering high-speed next generation DNA sequencing and ushering in the age of precision medicine. Anuncio • Feb 08
Quantum-Si incorporated to Report Q4, 2021 Results on Feb 28, 2022 Quantum-Si incorporated announced that they will report Q4, 2021 results After-Market on Feb 28, 2022 Recent Insider Transactions • Jan 14
CEO & Director? recently sold US$1.1m worth of stock On the 11th of January, John Stark sold around 180k shares on-market at roughly US$5.87 per share. This was the largest sale by an insider in the last 3 months. This was John's only on-market trade for the last 12 months. Board Change • Jan 01
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 1 experienced director. No highly experienced directors. Founder & Executive Chairman Jonathan Rothberg is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.